02 MAY 2017

CLINICAL TRIALS GUIDANCE

GUIDANCE ON DETERMINING WHETHER AN AMENDMENT TO A CLINICAL TRIAL IS A SUBSTANTIAL AMENDMENT

GN-CTB-2-003B-002
GUIDANCE ON DETERMINING WHETHER AN AMENDMENT TO A CLINICAL TRIAL IS A SUBSTANTIAL AMENDMENT

PREFACE
This document is intended to provide general guidance. Although we have tried to ensure that the information contained here is accurate, we do not, however, warrant its accuracy or completeness. The Health Sciences Authority (HSA) accepts no liability for any errors or omissions in this document, or for any action / decision taken or not taken as a result of using this document. If you need specific legal or professional advice, you should consult your own legal or other relevant professional advisers.

In the event of any contradiction between the contents of this document and any written law, the latter should take precedence.

CONTACT INFORMATION
For further information, please contact:
Clinical Trials Branch
Health Products Regulation Group
Health Sciences Authority
11 Biopolis Way, #11-01, Helios
Singapore 138667

Tel: 6866 3446
Fax: 6478 9034
Email: HSA_CT@hsa.gov.sg
Website: www.hsa.gov.sg
REVISION HISTORY

Guidance Version (Version Date)
GN-CTB-2-003B-001 (01 Nov 2016)
GN-CTB-2-003B-002 (02 May 2017)

SUMMARY OF AMENDMENTS

- Administrative changes made to Revision History, Section 1.2 and Section 6.
- Section 7.1: Change made to overall trial duration in “Protocol/ Informed Consent Form”.

TABLE OF CONTENTS

1. INTRODUCTION ................................................................................................................. 5
   1.1. Purpose ......................................................................................................................... 5
   1.2. Background ................................................................................................................ 5
   1.3. Scope .......................................................................................................................... 6

2. DEFINITIONS ..................................................................................................................... 7

3. WHY MUST SUBSTANTIAL AMENDMENTS BE SUBMITTED TO HSA? .............. 7

4. WHO SHOULD DETERMINE WHETHER AN AMENDMENT IS A SUBSTANTIAL AMENDMENT? .................................................................................................................. 8

5. WHAT ARE THE SUPPORTING DOCUMENTS REQUIREMENTS? ......................... 8

6. REFERENCES ..................................................................................................................... 10

7. APPENDIX ....................................................................................................................... 11
   7.1. Appendix A – Examples of Amendments ................................................................. 11
1. INTRODUCTION

1.1. Purpose
The purpose of this document is to provide guidance to clinical trial sponsors on determining whether an amendment to a clinical trial is a substantial amendment, and the supporting documents required for regulatory submission of a substantial amendment.

1.2. Background
The Health Sciences Authority regulates the conduct of clinical trials of therapeutic products and medicinal products under the Health Products (Clinical Trials) Regulations and the Medicines (Clinical Trials) Regulations respectively. The Regulations require sponsors of clinical trials to submit details of the clinical trials to HSA under one of 3 submission routes:
• clinical trial authorisation (CTA - for clinical trials of therapeutic products)
• clinical trial notification (CTN - for clinical trials of therapeutic products used in accordance with approved label),
• clinical trial certificate (CTC - for clinical trials of medicinal products)

For determination of the requirements, please refer to the Guidance on Determination of Whether a Clinical Trial Requires a Clinical Trial Authorisation (CTA), Clinical Trial Notification (CTN) or a Clinical Trial Certificate (CTC).

After CTA, acceptance of CTN or a CTC has been granted by HSA, the sponsor of the trial may make amendments to the clinical trial as needed for various reasons, including, but not limited to, ensuring the continued safety of trial subjects, clarifying study procedures or patient eligibility criteria and/or accommodating changing development strategies.

Trial amendments may be substantial or non-substantial. The Health Products (Clinical Trials) Regulations and the Medicines (Clinical Trials) Regulations
(henceforth referred to as “the Regulations”) define a substantial amendment as an amendment –

(a) Which changes a sponsor or principal investigator of the trial; or
(b) Which is likely to affect to a significant degree –
   (i) The safety, or physical or mental integrity, of any subject of the trial;
   (ii) The scientific value of the trial;
   (iii) The conduct or management of the trial; or
   (iv) The quality or safety of any investigational product used in the trial.

Sponsors are required to submit all substantial amendments of the trial to Health Sciences Authority (HSA) for approval or acceptance of notification. The sponsor must not implement any substantial amendment before HSA approval (for authorised clinical trials or trials issued with a Clinical Trial Certificate) or HSA acceptance of notification of the substantial amendment (for notified clinical trials), unless the amendment is to protect any subject of a clinical trial against any immediate hazard to the health or safety of the subject (i.e. urgent safety measure).

In addition, the sponsor is required to keep records of all substantial and non-substantial amendments to the trial, and provide such records to HSA if requested.

1.3. Scope
This guidance applies to substantial amendments to the clinical trials regulated by HSA, namely:
(i) Clinical trials of Therapeutic Products that are subject to the requirements for a Clinical Trial Authorisation (CTA) or a Clinical Trial Notification (CTN);
(ii) Clinical trials of Medicinal Products (e.g. Cell, Tissue and Gene Therapy Products; or Complementary Health Products) that are subject to the requirements of a Clinical Trial Certificate (CTC).
2. DEFINITIONS

- “amendment” means an amendment to —
  (a) any term of an application for certification to conduct a clinical trial; or
  (b) any particulars or documents (including a protocol) accompanying that application;

- “substantial amendment”, in relation to a clinical trial, means an amendment —
  (a) which changes a sponsor or principal investigator of the trial; or
  (b) which is likely to affect to a significant degree —
    (i) the safety, or physical or mental integrity, of any subject of the trial;
    (ii) the scientific value of the trial;
    (iii) the conduct or management of the trial; or
    (iv) the quality or safety of any investigational therapeutic product used in the trial

3. WHY MUST SUBSTANTIAL AMENDMENTS BE SUBMITTED TO HSA?

As substantial amendments to a clinical trial have the potential to affect the benefit-risk assessment of the trial, they should be subjected to a review process similar to the initial clinical trial application and must not be implemented before approval (for authorised clinical trials or trials issued with CTC) or acceptance of notification (for notified trials) by HSA, unless it is an urgent safety measure. Conversely, non-substantial amendments need not be submitted to HSA unless specifically requested by HSA. HSA’s approval or acceptance of notification is not required prior to implementation, if applicable, of non-substantial amendments (Figure 1).
Appendix A provides examples of amendments that may be considered as substantial. These examples may help the sponsor to determine whether the amendment should be approved or accepted by HSA before implementation.

4. WHO SHOULD DETERMINE WHETHER AN AMENDMENT IS A SUBSTANTIAL AMENDMENT?
It is the sponsor’s responsibility to assess whether an amendment is regarded as substantial and to comply with the submission requirements. This assessment should be documented, as the appropriateness of the determination by the sponsor may be reviewed by HSA. The sponsor should consult HSA for advice when in doubt.

The sponsor is required to keep records of all substantial and non-substantial amendments to the trial, and provide such records to HSA if requested.

5. WHAT ARE THE SUPPORTING DOCUMENTS REQUIREMENTS?
The sponsor of the clinical trial should ensure that the details and rationale for the amendment(s) are clearly described in the submission. This can take the form of a summary table and/or tracked change version of the original/approved document. Table 1 illustrates the supporting documents that should be attached in the PRISM submission.
Table 1. Supporting documents for substantial amendments

<table>
<thead>
<tr>
<th>Type of substantial amendments</th>
<th>Supporting documents</th>
</tr>
</thead>
</table>
| Amendment to Protocol                                                | • Clinical Trial Protocol Amendment  
• Summary of Protocol Amendment  
• IRB Approval Letter [Mandatory for CTN]                                                                 |
| Amendment to Informed Consent Form                                  | • Revised Informed Consent Form  
• Track Change Version for Informed Consent Form  
• IRB Approval Letter [Mandatory for CTN]                                                                 |
| Change of Local Sponsor                                             | • Letter from the current local sponsor indicating transfer of local sponsorship to the new local sponsor  
• IRB Approval Letter [Mandatory for CTN]                                                                 |
| Change of Principal Investigator                                     | • Curriculum Vitae of Principal Investigator  
• Informed Consent Form, if revised  
• IRB Approval Letter [Mandatory for CTN]                                                                 |
| Addition of Trial Site                                               | • Curriculum Vitae of Principal Investigator  
• Informed Consent Form (for new trial site)  
• IRB Approval Letter [Mandatory for CTN]                                                                 |
| Change of Manufacturer                                               | • For change/ addition of a manufacturer not licensed/ certified by HSA,  
  ○ Good Manufacturing Practice (GMP) certificate; or  
  ○ Where the GMP certificate is not available, a declaration by the manufacturer of its compliance with cGMP, and the Certificate of Analysis of the product manufactured by the new manufacturer |
| Change of Chemistry, Manufacturing, Controls (CMC) Information       | • Supporting CMC information, where relevant                                                                                                         |
6. REFERENCES

(i) Health Products (Clinical Trials) Regulations
(ii) Medicines (Clinical Trials) Regulations
(iii) European Commission - Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1)
(iv) Guidance on Determination of Whether a Clinical Trial Requires a Clinical Trial Authorisation (CTA), Clinical Trial Notification (CTN) or a Clinical Trial Certificate (CTC)
7. Appendix

7.1. Appendix A – Examples of Amendments

The following table illustrates examples of amendments that may be considered as substantial or non-substantial amendments. The list serves as an aid to guide whether submission to HSA is required. This is not an exhaustive list.

<table>
<thead>
<tr>
<th>Type of amendment</th>
<th>Scope of amendments</th>
<th>Substantial amendments requiring submission?</th>
</tr>
</thead>
</table>
| Protocol/Informed Consent Form | - Change of main study objective  
- Change of primary or secondary endpoint which is likely to have a significant impact to  
  (i) the safety, or physical or mental integrity, of any subject of the trial;  
  (ii) the scientific value of the trial;  
  (iii) the conduct or management of the trial  
- Use of a new measurement for primary endpoint  
- New toxicological or pharmacological data or new interpretation of these data which is likely to impact the risk/benefit assessment  
- Change in the definition of the end of the trial, even if the trial has in practice already ended  
- Changes to inclusion/exclusion criteria such as changes to age range, if these changes are likely to have a significant impact on the safety or scientific value of the clinical trial or the conduct or management of the trial  
- Addition of treatment arm (including placebo)  
- Changes relating to the Investigational Product (e.g. change of Investigational Product, doses, mode of administration)  
- Reduction of number of subject monitoring visits  
- Change of a diagnostic or medical monitoring procedure which is likely to have a significant impact on the safety or scientific value of the trial | Yes. Such amendment is typically considered as a substantial amendment. |
<table>
<thead>
<tr>
<th>Type of amendment</th>
<th>Scope of amendments</th>
<th>Substantial amendments requiring submission?</th>
</tr>
</thead>
</table>
| Protocol/ Informed Consent Form   | - Change in the **overall** sample size for the trial  
- Withdrawal of an independent data monitoring board  
- Change of study design which is likely to have a significant impact on primary or major secondary statistical analysis or the risk/benefit assessment  
- Any change in study design that fulfils the criteria for ‘substantial amendment’ | No. Such amendment is typically not considered as a substantial amendment. |
| Change of Local Sponsor/ Principal Investigator/ Addition of Trial Site | - Changes to identification of trial (e.g. change of protocol title, protocol number)  
- Change in (competitive) enrolment target in Singapore site, but overall sample size for the trial remains unchanged  
- Change to overall trial duration, provided that:  
  (i) the subject’s exposure to treatment with Investigational Product is not extended;  
  (ii) the definition of end of the trial in protocol is unchanged  
  (iii) subject monitoring frequency and procedures are unchanged  
- Addition or deletion of overseas sites (not as a result of safety concerns)  
- Correction of typographical errors | Yes. Such amendment is typically considered as a substantial amendment. |
| Change of Chemistry, Manufacturing, Controls (CMC) Information [if the | - Change of local trial sponsor  
- Change of principal investigator  
- Addition of local trial site and principal investigator  
- Change of address of local trial site | Yes, if the CMC information had been submitted in the initial clinical trial application. |
|                                    | Importation of the medicinal product  
- Change of name or code of IMPs  
- Immediate packaging material  
- Manufacturer(s) of drug substance | |

HEALTH SCIENCES AUTHORITY – HEALTH PRODUCTS REGULATION GROUP
<table>
<thead>
<tr>
<th>Type of amendment</th>
<th>Scope of amendments</th>
<th>Substantial amendments requiring submission?</th>
</tr>
</thead>
</table>
| CMC information had been submitted in the initial clinical trial application | - Manufacturing process of the drug substance  
- Specifications of active substance  
- Manufacture of the medicinal product  
- Specification (release or shelf-life) of the medicinal product  
- Specification of excipients where these may affect product performance  
- Shelf-life including after first opening and reconstitution  
- Major change to the formulation  
- Storage conditions  
- Test procedures of active substance  
- Test procedures of the medicinal product  
- Test procedures of non-pharmacopoeial excipients |  |
| Contact information for local sponsor | - Change in contact person  
- Change in email, phone number, fax or postal address of contact person  
- Change of monitor  
- Change of Contract Research Organisation (CRO), provided the CRO is not a local sponsor | No. This is not considered as an amendment, if the local sponsor remains the same. |
| Contact information for Principal investigator | - Change in email, phone number or fax of principal investigator | No. This is not considered as an amendment, if the principal investigator and site address remains the same. |
CONTACT INFORMATION:
Clinical Trials Branch
Health Products Regulation Group
Health Sciences Authority

11 Biopolis Way, #11-03, Helios
Singapore 138667
Tel: 6866 3446
Fax: 6478 9034
Email: HSA_CT@hsa.gov.sg
Website: www.hsa.gov.sg